Faruqi & Faruqi, LLP Launches An Investigation Against Hemispherx Biopharma, Inc. (HEB) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hemispherx Biopharma, Inc. (“Hemispherx” or the “Company”) (NYSE MKT: HEB) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for the HEMISPHERx 2013 Equity Incentive Plan.
Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on September 16, 2013, the Board of Directors recommends that Hemispherx’s shareholders vote to approve the HEMISPHERx 2013 Equity Incentive Plan. A maximum of 15,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the Equity Incentive Plan. The issuance of the additional shares could have a substantial dilutive effect on the shares of Hemispherx common stock.
If you own common stock in Hemispherx and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.